HS SynBio key facts
- Developer of synthetic genetic element mining technology designed for synthetic biology.
- Notable investors include Haihe River Industry Fund, Renai Capital, Bohai Chuangfu Securities Investment, Tianjin Kechuang.
- Status: Privately Held (backing).
- ·Watch HS SynBio: the Monday email on marks, rounds and moves
HS SynBio funding rounds
No funding rounds for HS SynBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
HS SynBio investors
4 investors are on record for HS SynBio, including Haihe River Industry Fund, Renai Capital, Bohai Chuangfu Securities Investment and Tianjin Kechuang.
About HS SynBio
Developer of synthetic genetic element mining technology designed for synthetic biology. The company's products mainly focus on innovations in synthetic genetic element mining technology, genome editing technology, efficient protein expression technology, omics analysis technology, thereby providing customers with innovative products.
- Sector
- Healthcare
- HQ
- Tianjin, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
HS SynBio doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.